Clinical Research in Houston, TX

Researching Treatments for Hypothyroidism Care

Do you suffer from Hypothyroidism? Researchers are studying an investigational product to assess its effects on thyroid hormone levels and quality of life.

Qualifications:

• 18-75 years old
• Have been diagnosed with primary hypothyroidism
• Have been on continuous thyroid replacement therapy with levothyroxine for at least 12 months

Requirements:

• You will receive study treatment.
• There will be 12 visits with your doctor.

You will be compensated for your time for study visits and laboratory sample collections.

Have you been diagnosed with Pulmonary Hypertension due to COPD?

Qualifications:

• 18 years of age or older
• Must have an established diagnosis of chronic obstructive pulmonary disease (COPD) with suspected or confirmed pulmonary hypertension
• Must be able to walk at least 100 meters during a 6-minute walk test without limitations in mobility using no oxygen or oxygen at no more than 10 liters per minute
• Willing and able to use Sponsor provided devices (actigraph, spirometer, and smart device)

Requirements:

• Willing to undergo Right Heart Catheterization
• Inhaled Treprostinil for PH-COPD

FSGS is a type of kidney disease that occurs when scar tissue develops on the parts of your kidneys that act as filters (the glomeruli). The scar tissue makes it more difficult for the filters to do their job. Instead of keeping essential proteins in your body, the injured filters allow these proteins to flow into the urine. This can lead to high levels of protein in your urine, a condition called proteinuria.

Podocytes are cells lining the kidney that, in their normal state, prevent proteinuria. Injury to, and loss of, podocytes is a central component of FSGS. Protecting podocytes from further injury, and stopping proteinuria, may help slow the progression of kidney disease and potentially prevent kidney failure.

What is the purpose of this trial?

Currently, there is no approved therapy in the US to treat Focal Segmental Glomerulosclerosis (FSGS). Advances in drug therapy are key to treating FSGS in its early stages and preventing further kidney damage. The TRACTION-2 Trial is testing an investigational medication (GFB-887) that has the potential to reduce the amount of protein in urine and preserve kidney function in patients with kidney disease. If you have FSGS, this trial may be an option for you.

Qualifications:

• 18 to 75 years of age
• Have been diagnosed or are being treated for FSGS
• Have high levels of protein in your urine (proteinuria)

Requirements:

Diagnosis based on documented biopsy or genetic testing and currently receiving ACE inhibitor or ARB for 3 months.

Diagnosed with OAB? Participate in a clinical study for a new wearable OAB device.

Qualifications:

• 18 years of age or older
• Diagnosed with Overactive Bladder
• Have an average of 11 urinary frequency events per day
• Have daily access to WiFi

Requirements:

Wearing an investigational device for 30 minutes 1 to 3 times per week in your home.

12-week study period

This study looks at different strengths of a potential new investigational vaccine against chickenpox (varicella). The study will look at how safe the study vaccine is and will also determine whether it works to help prevent chickenpox in children.

Why is this study important?

Chickenpox is a very contagious infection that can cause serious complications in children. Access to several chickenpox vaccines is important because vaccination is the only way to help protect children from chickenpox.

Qualifications:

• Your child may be able to take part if they:
• Are 12-15 months of age
• Are in good health
• Have received the first 3 doses (primary series) of a pneumococcal conjugate vaccine, a vaccine against infections caused by the Streptococcus pneumoniae bacteria, which cause ear, lung, and other infections.

Requirements:

If your child takes part, they will be in this study for about 6 months. Your child will need to:

Complete 3 study visits and 2 phone contacts for safety follow-up.

Receive the study vaccine or reference vaccine and 3 other approved vaccines that are part of routine vaccination schedules:

M-M-R II against measles, mumps, and rubella

Havrix against hepatitis A infection

Prevnar 13, a pneumococcal conjugate vaccine, against infections caused by the Streptococcus pneumoniae bacteria, which cause ear, lung, and other infections

Have 1 blood sample collected about 6 weeks after vaccination.

Systemic Lupus Erythematosus (SLE), also known as “lupus,” is an autoimmune disease that affects multiple organ systems and is unpredictable in disease severity, with periods of illness or flares alternating with periods of remission. The presentation of lupus can affect many different parts of the body but frequently involves the joints, skin, kidneys, blood cells, and mucus membranes (the lining of the mouth, nose, throat, stomach, and intestines) which can result in symptoms such swollen joints, rash, foamy urine, changes in red or white blood cells, and oral ulcers, among others. Disease prevalence is approximately 1 in 1,000 individuals overall but varies with race and ethnicity.

What is the purpose of this trial?

Most therapies used to treat SLE are only partially effective and have considerable toxicity. The purpose of the study is to investigate if the investigational product, BIIB059, can reduce disease activity and inflammation in people with active SLE compared to a placebo. BIIB059 is a type of antibody that has been developed to target certain cells that are thought to play a role in the development of lupus. It is hoped the study drug can improve symptoms in people with SLE.

Qualifications:

• Participants must be at least 18 years of age
• Have been diagnosed with moderate-to-severe SLE for at least 6 months
• Are currently taking SLE medication

Requirements:

You will receive an investigational product via injections under the skin every month.

Visits will last about a year and a half and include around 22 visits to the study site.